Tetracaine
Systematic (IUPAC) name | |
---|---|
2-(dimethylamino)ethyl 4-(butylamino)benzoate | |
Clinical data | |
AHFS/Drugs.com | monograph |
MedlinePlus | a682640 |
Legal status |
|
Routes of administration | Topical, Epidural, Spinal |
Pharmacokinetic data | |
Protein binding | 75.6 |
Identifiers | |
CAS Number |
94-24-6 136-47-0 (hydrochloride) |
ATC code | C05AD02 D04AB06 N01BA03 S01HA03 |
PubChem | CID 5411 |
ChemSpider | 5218 |
UNII | 0619F35CGV |
KEGG | D00551 |
ChEBI | CHEBI:9468 |
ChEMBL | CHEMBL698 |
PDB ligand ID | TE4 (PDBe, RCSB PDB) |
Chemical data | |
Formula | C15H24N2O2 |
Molar mass | 264.363 g/mol |
| |
| |
(verify) |
Tetracaine (INN, also known as amethocaine; trade name Pontocaine. Ametop and Dicaine) is a potent local anesthetic of the ester group. It is mainly used topically in ophthalmology and as an antipruritic, and it has been used in spinal anesthesia.
In biomedical research, tetracaine is used to alter the function of calcium release channels (ryanodine receptors) that control the release of calcium from intracellular stores. Tetracaine is an allosteric blocker of channel function. At low concentrations, tetracaine causes an initial inhibition of spontaneous calcium release events, while at high concentrations, tetracaine blocks release completely.[1]
Tetracaine is the T in Tac, a mixture of 5 to 12 per cent tetracaine, 0.05 per cent adrenaline, and 4 or 10 per cent cocaine hydrochloride used in ear, nose & throat surgery and in the emergency department where numbing of the surface is needed rapidly, especially when children have been injured in the eye, ear, or other sensitive locations.[2]
It is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system.[3]
A systematic review investigated tetracaine for use in emergency departments, especially for IV cannulation in children, in view of its analgesic and cost-saving properties - however it did not find a statistically significant improvement in first attempt cannulations.[4]
References
- ↑ Györke, S; Lukyanenko, V; et al. (1997). "Dual effects of tetracaine on spontaneous sodium release in rat ventricular myocytes" 500 (2). J Physiol: 297–309.
- ↑ Appleton's Nursing Manual - "Cocaine"
- ↑ "WHO Model List of EssentialMedicines" (PDF). World Health Organization. October 2013. Retrieved 22 April 2014.
- ↑ Pywell, A; Xyrichis, A (2014). "Does topical Amethocaine cream increase first-time successful cannulation in children compared with a eutectic mixture of local anaesthetics (EMLA) cream? A systematic review and meta-analysis of randomised controlled trials" 0 (0). Emerg Med J: 1–5. doi:10.1136/emermed-2014-204066.
Further reading
- O. Eisleb, U.S. Patent 1,889,645 (1932).
|